Compatibility of tirofiban HCl with dopamine HCl, famotidine, sodium heparin, lidocaine HCl and potassium chloride during simulated Y-site administration

Objective: To study the compatibility of tirofiban HCl injection 0.05 mg/ml with dopamine HCl, famotidine, sodium heparin, lidocaine HCl and potassium chloride infusion solutions during simulated Y-site administration. Method: Tirofiban HCl, dopamine HCl, famotidine, lidocaine HCl and potassiu m chloride infusions were each prepared from their respective concentrates as per current clinical preparation instructions in both 0.9% sodium chlori de and 5% dextrose solutions at both the minimum and maximum concentrations normally administered. Sodium heparin premixed infusion solutions in 5% de xtrose and 0.45% sodium chloride were used as-is. Tirofiban HCl solutions w ere combined 1:1 (simulated Y-site administration) with the dopamine HCl, f amotidine, sodium heparin, lidocaine HCl and potassium chloride solutions i n separate glass containers and polyvinylchloride Y-site infusion lines. Sa mples were held for 4 h at room temperature under ambient fluorescent light and were assayed for changes in drug content, degradation, pH, appearance and turbidity. Activity of sodium heparin solutions was measured using an a PTT coagulation assay. Results: All mixtures remained clear and colourless with no visual indicati on of instability, i.e. precipitation. Clarity of solutions was confirmed b y turbidometric analysis. There was no significant loss of drug, increase i n known degradates, or appearance of unknown drug-related peaks as determin ed by HPLC. The activity of heparin in heparin-containing solutions remaine d unchanged. The pH of all test-solutions remained constant. Conclusion: Tirofiban HCl injection 0.05 mg/ml can be co-infused by Y-site administration with dopamine HCl, famotidine, sodium heparin, lidocaine HCl and potassium chloride injection solutions.